A novel derivative of rhein overcomes temozolomide resistance in glioblastoma by regulating SOX9 through m6A methylation
Brain Research · 2025
DOI: 10.1016/j.brainres.2025.149889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2025. Verfasst von Li Cheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Drug Resistance, Neoplasm, SOX9 Transcription Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Temozolomide (TMZ) resistance remains a critical barrier to effective treatment of glioblastoma (GBM), the most aggressive form of glioma. Fat mass and obesity-associated protein (FTO), an m6A demethylase, has been implicated in tumor progression and chemoresistance. SYSUP007, a novel derivative of the FTO inhibitor rhein, exhibits anti-glioma activity; however, its role in modulating TMZ resistance remains unexplored. The present study aimed to investigate the mechanism by which SYSUP007 regulates TMZ resistance via FTO signaling. TMZ-resistant glioma cells were subjected to combinatorial treatment with SYSUP007 and TMZ. Cell proliferation was assessed using the MTT assay, while m6A dot blotting was employed to evaluate global m6A methylation levels. Western blotting and reverse transcription-polymerase chain reaction (RT-PCR) were performed to analyze FTO and downstream target expression. The results revealed that SYSUP007 inhibited glioma cell proliferation in a dose-dependent manner and synergistically enhanced TMZ sensitivity in vitro. SYSUP007 significantly suppressed FTO expression and elevated m6A methylation levels, concomitant with downregulation of the oncogenic FTO target SOX9. Notably, SOX9 expression was markedly upregulated in TMZ-resistant cells compared with parental cells, and SYSUP007 effectively reversed this phenotype. These findings suggest that SYSUP007 potentiates TMZ efficacy by targeting the FTO/m6A/SOX9 axis. As a single-molecule multi-target agent, SYSUP007 represents a promising therapeutic candidate to overcome TMZ resistance in glioma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China.
- School of Medicine, Sun Yat-sen University, Shenzhen 528406, PR China.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China. Electronic address: plzhao@smu.edu.cn.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, PR China. Electronic address: bigtree888@smu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cheng, L., Wang, T., Pi, R., Zhao, P., & Chen, J. (2025). A novel derivative of rhein overcomes temozolomide resistance in glioblastoma by regulating SOX9 through m6A methylation. Brain Research. https://doi.org/10.1016/j.brainres.2025.149889
Vancouver
Cheng L, Wang T, Pi R, Zhao P, Chen J. A novel derivative of rhein overcomes temozolomide resistance in glioblastoma by regulating SOX9 through m6A methylation. Brain Research. 2025. doi:10.1016/j.brainres.2025.149889
BibTeX
@article{Cheng2025,
author = {Cheng, Li and Wang, Ting and Pi, Rongbiao and Zhao, Peiliang and Chen, Jingkao},
title = {A novel derivative of rhein overcomes temozolomide resistance in glioblastoma by regulating SOX9 through m6A methylation},
journal = {Brain Research},
year = {2025},
doi = {10.1016/j.brainres.2025.149889}
}
EUVIMED